Literature DB >> 28344047

Sub-additive effects of photodynamic therapy combined with erlotinib for the treatment of epidermoid carcinoma: An in vitro study.

Sávio M L Gontijo1, Renata C Felizali1, Pedro P G Guimarães2, Robson A S Santos3, Rubén D Sinisterra2, Maria E Cortés1, Patrícia V Araújo4.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is an antitumour treatment that employs the combination of a photosensitive compound, oxygen and visible light. To improve the antitumour activity of PDT, the present study used the strategy of combining PDT with erlotinib (ERL), a drug frequently used in the treatment of epidermoid carcinoma.
METHODS: An MTT cell viability assay was used to evaluate the cytotoxicity of PDT combined with ERL on A431 epidermoid carcinoma cells in vitro. This study evaluated the cytotoxicity of the following treatments: red laser irradiation (660nm) at different power densities (1.25-180J/cm2), the photosensitizer methylene blue (MB) at concentrations of 0.39-100μM, PDT (12.5μM MB and laser power densities from 1.25 to 180J/cm2), and PDT (12.5μM MB and a laser density of 120J/cm2) plus ERL (1μM).
RESULTS: The laser power densities that were tested showed no cytotoxicity in A431 cells. MB showed a dose-dependent cytotoxicity. In PDT, an increase in the dose of light resulted in an increase in the cytotoxicity of MB. In addition, there was a sub-additive effect between PDT and ERL compared to the effect of each therapy alone.
CONCLUSIONS: The sub-additive effect between PDT and ERL suggests that their combination may be an important strategy in the treatment of epidermoid carcinoma.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  A431 epidermoid carcinoma; Erlotinib; Methylene blue; Photodynamic therapy

Mesh:

Substances:

Year:  2017        PMID: 28344047     DOI: 10.1016/j.pdpdt.2017.03.010

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  2 in total

1.  Peroxoniobium inhibits leukemia cell growth.

Authors:  Elene C Pereira-Maia; Ivina P Souza; Kelen J R C Nunes; Alexandre A Castro; Teodorico C Ramalho; Fernando Steffler; Helio A Duarte; Ana Pacheli; Poliana Chagas; Luiz C A Oliveira
Journal:  RSC Adv       Date:  2018-03-14       Impact factor: 3.361

2.  Tumor Cell-Specific Retention and Photodynamic Action of Erlotinib-Pyropheophorbide Conjugates.

Authors:  Erin C Tracy; Ravindra R Cheruku; Ravindra K Pandey; Heinz Baumann
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.